NewAmsterdam Pharma Company N.V.

NAMS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$40$0-$40-$92
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$15$15$15$9
Change in WC-$10-$24$10-$8
Other Non-Cash-$77-$29-$23$53
Operating Cash Flow-$33-$38-$36-$37
Investing Activities
PP&E Inv.-$0-$0-$0-$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$32-$184-$10$0
Inv. Sales/Matur.$34$25$13$0
Other Inv. Act.$0$0$0-$62
Investing Cash Flow$3-$159$3-$62
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$6$3$0$455
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$7$2
Financing Cash Flow$6$3$7$457
Forex Effect$0$9$4-$8
Net Chg. in Cash-$24-$185-$23$349
Supplemental Information
Beg. Cash$564$748$772$423
End Cash$540$564$748$772
Free Cash Flow-$33-$38-$36-$37
NewAmsterdam Pharma Company N.V. (NAMS) Financial Statements & Key Stats | AlphaPilot